ClinicalTrials.gg
DrugRead study by study

Alectinib clinical trials

Also written Alecensa, RO5424802 and RG7853.

studies test it
59
open now
19
in phase 3
11
first study started
2013
ClinicalTrials.gov finds 100 studies for alectinib. How that becomes 59 hereChecked on ClinicalTrials.gov

Every study that search finds has been read, to see whether and how it gives alectinib. Its counts are asked again every night. How drug pages count

  1. 100Found by its intervention search · See all 100 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 78 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −11
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 89Give alectinib to participants
  4. −16Observe patients on it, or give it outside a trial
  5. −2Compare another treatment with it
  6. −12Give it beside what is tested
  7. 59Test it: the count on this site

Get an email when these change. Save the alectinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
11 Dec 2015 · ALECENSA · NDA 208434 (FDA, Drugs@FDA)
European Union
16 Feb 2017 · Alecensa · EMEA/H/C/004164 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Alectinib
43
Alectinib 150 MG
2

Brand

Alecensa
19

Development codes

RO5424802
12
RG7853
2
CH5424802
2
RO5452802
1
AF-802
1

Studies by the year they started

59 studies that test it; most in 2021 (9)

Studies that test alectinib, by start year
YearStudies
20136
20144
20153
20162
20176
20183
20192
20207
20219
20225
20233
20243
20251
20265

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
18
Phase 2
38
Phase 3
11
Phase 4
1
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 25 · Other 34

Hoffmann-La Roche (21) · Genentech, Inc. (3) · Massachusetts General Hospital (2) · China Medical University Hospital (2) · The Netherlands Cancer Institute (2) · Instituto Nacional de Cancerologia de Mexico (2) · Cancer Research UK (2) · Hunan Province Tumor Hospital (2)

Often tested with

Tested in the same studies.

Atezolizumab (16) · Entrectinib (13) · Cobimetinib (11) · Vemurafenib (10) · Trastuzumab (10) · Pertuzumab (9) · Crizotinib (7) · HhAntag691 (6)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 1 most studied

New when their studies opened, with alectinib beside them; studies of each.

Reaching primary completion within a year · 7, 3 in phase 3

Studies that test alectinib, phase 3 first.

Studies

Open first, then newest update. How each study uses alectinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 59

See all 59 studies that test alectinib →

Behind its US label · 3 — the studies the FDA label of ALECENSA describes

From the Clinical Studies section of ALECENSA (2026-08), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 18 — no other medicine in its arm
Tested with established drugs · 6 — they are given beside it
Tested in a combination · 32 — another drug in the study is under test too

Showing 20 of 32. See all 32 →

Beside an established treatment under test · 2 — an approved drug, surgery or radiation is what the study tests

Tested with alectinib: Radiation 2

Beside a new treatment under test · 2 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with alectinib: datopotamab deruxtecan 1

Beside supportive care · 3 — a supportive treatment or test is studied
One option of several · 5 — a test or a strategy chooses among drugs
As the comparator · 2 — what is tested is compared with alectinib
Observed · 16 — patients on it are followed, or it is given outside a trial

What changed recently

From the registry's own updates since Oct 19, 2026.

Codes

What other systems call alectinib · ClinicalTrials.gg INT006325

  • MeSH (NLM) C582670alectinibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) LIJ4CT1Z3YALECTINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1727455Confirmed FDA, Wikidata
  • Wikidata Q21099132alectinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C101790AlectinibOne source FDA
  • DrugBank DB11363One source Wikidata

Also registered as alectinib hydrochloride (UNII P9YY73LO6J · RxNorm 1727454).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion